An Isologous Porcine Promoter Permits High Level Expression of Human Hemoglobin in Transgenic Swine

Overview

Journal Biotechnology (N Y)

Specialty Biotechnology

Date 1994 Jan 1

PMID 7764326

Citations 16

Authors

A Sharma

M J Martin

J F Okabe

R A Truglio

N K Dhanjal

J S Logan

R Kumar

Affiliations

Soon will be listed here.

Abstract

We describe isologous promoter replacement as an approach to permit high level expression of human hemoglobin in transgenic swine. We linked the human beta globin genomic coding region to the porcine beta globin promoter and used this fusion gene in an expression construct containing the human beta locus control region and the human alpha and epsilon genes to produce transgenic pigs. The highest level of expression was 24% human (32g/liter) and 30% human alpha/pig beta hybrid (40g/liter) hemoglobin in one transgenic pig. This pig was bred to a non-transgenic animal resulting in the transmission of high level human hemoglobin expression to 5 of 12 progeny.

Citing Articles

The Effects of Mammary Gland Overexpression on the General Health of Dairy Goats and Their Anti-Inflammatory Response to LPS Stimulation.

Yan L, Wu H, Guan S, Ma W, Fu Y, Ji P Int J Mol Sci. 2023; 24(20).

PMID: 37894983 PMC: 10607088. DOI: 10.3390/ijms242015303.

Porcine germline genome engineering.

Yang L, Church G, Zhao H, Huang L, Gao Y, Wei H Proc Natl Acad Sci U S A. 2021; 118(22).

PMID: 34050015 PMC: 8179169. DOI: 10.1073/pnas.2004836117.

Application of Genetically Engineered Pigs in Biomedical Research.

Hryhorowicz M, Lipinski D, Hryhorowicz S, Nowak-Terpilowska A, Ryczek N, Zeyland J Genes (Basel). 2020; 11(6).

PMID: 32575461 PMC: 7349405. DOI: 10.3390/genes11060670.

Comparison of the oxidative reactivity of recombinant fetal and adult human hemoglobin: implications for the design of hemoglobin-based oxygen carriers.

Simons M, Gretton S, Silkstone G, Rajagopal B, Allen-Baume V, Syrett N Biosci Rep. 2018; 38(4).

PMID: 29802155 PMC: 6028758. DOI: 10.1042/BSR20180370.

The transgenic animal platform for biopharmaceutical production.

Bertolini L, Meade H, Lazzarotto C, Martins L, Tavares K, Bertolini M Transgenic Res. 2016; 25(3):329-43.

PMID: 26820414 DOI: 10.1007/s11248-016-9933-9.